Andira Pharmaceuticals develops cannabinoid‑based therapeutics and medical devices that use synergistic cannabinoid combinations to improve outcomes for post‑surgical pain, chronic wounds, and early‑stage breast cancer. Their pipeline includes a transdermal analgesic (AND‑254), a localized breast‑cancer therapy (AND‑259), and the Silvanex™ platform, a triple‑synergy silver‑cannabinoid formulation that provides broad antimicrobial activity and promotes tissue repair.
Funding
$393.1K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients undergoing surgery, those with chronic diabetic ulcers, and individuals with early-stage breast cancer often face limited treatment options, high rates of infection, prolonged pain, and the risk of antimicrobial resistance, leading to poor outcomes and increased healthcare costs.
Solution
Andira Pharmaceuticals develops cannabinoid‑based therapeutics and medical devices that leverage synergistic combinations of cannabinoids with other agents to enhance efficacy. Their pipeline includes a transdermal formulation (AND‑254) for post‑mastectomy pain, a cannabinoid‑targeted therapy (AND‑259) for ductal carcinoma in situ, and the Silvanex™ platform—a triple‑synergy blend of silver, cannabichromene and cannabigerol that provides broad‑spectrum antibacterial and antifungal activity while promoting wound healing. These products are designed for local delivery to maximize therapeutic effect, reduce systemic side effects, and overcome antimicrobial resistance in surgical and chronic wound settings.
Target Audience
Primary customers are hospitals, surgical centers, and wound‑care clinics seeking advanced infection‑control solutions, as well as oncologists and breast‑cancer surgeons looking for non‑opioid pain management and adjunctive therapies for early‑stage breast cancer.
Features
- Transdermal delivery system in AND‑254 that targets peripheral cannabinoid receptors at the surgical site for multimodal analgesia and anti‑inflammation
- AND‑259 utilizes cannabinoid‑mediated inhibition of CDK‑1 and PI3K/Akt pathways, delivering localized treatment to DCIS lesions via a novel drug‑delivery technology
- Silvanex™ antimicrobial technology combines silver with CBC and CBG to achieve >800% increased efficacy against Gram‑positive, Gram‑negative bacteria and fungi, including resistant biofilms
- Dual anti‑infective and wound‑healing action in Silvanex™ topical cream for diabetic ulcers, eradicating microbes while enhancing cellular viability for tissue repair
- Hospital‑grade Silvanex™ wound dressings provide sustained antimicrobial protection with lower silver content and a cell‑wall targeting mechanism to prevent resistance emergence
- Patent‑protected library of cannabinoid‑drug and cannabinoid‑cannabinoid formulations enabling customized synergy for infection control and cancer therapy